scholarly journals Fatty Acid Unsaturation Degree of Plasma Exosomes in Colorectal Cancer Patients: A Promising Biomarker

2021 ◽  
Vol 22 (10) ◽  
pp. 5060
Author(s):  
Joan Bestard-Escalas ◽  
Rebeca Reigada ◽  
José Reyes ◽  
Paloma de la Torre ◽  
Gerhard Liebisch ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Successful Implementation ◽  
Hyperplastic Polyps ◽  
Clinical Context ◽  
Healthy Group ◽  
Screening Programs ◽  
Non Invasive ◽  
Potential Source ◽  
Colorectal Cancer Patients ◽  
Detection Strategies

Even though colorectal cancer (CRC) is one of the most preventable cancers, it is currently one of the deadliest. Worryingly, incidence in people <50 years has increased unexpectedly, and for unknown causes, despite the successful implementation of screening programs in the population aged >50 years. Thus, there is a need to improve early diagnosis detection strategies by identifying more precise biomarkers. In this scenario, the analysis of exosomes is given considerable attention. Previously, we demonstrated the exosome lipidome was able to classify CRC cell lines according to their malignancy. Herein, we investigated the use of the lipidome of plasma extracellular vesicles as a potential source of non-invasive biomarkers for CRC. A plasma exosome-enriched fraction was analyzed from patients undergoing colonoscopic procedure. Patients were divided into a healthy group and four pathological groups (patients with hyperplastic polyps; adenomatous polyps; invasive neoplasia (CRC patients); or hereditary non-polyposis CRC. The results showed a shift from 34:1- to 38:4-containing species in the pathological groups. We demonstrate that the ratio Σ34:1-containing species/Σ38:4-containing species has the potential to discriminate between healthy and pathological patients. Altogether, the results reinforce the utility of plasma exosome lipid fingerprint to provide new non-invasive biomarkers in a clinical context.

scholarly journals Non‐invasive metastasis prognosis from plasma metabolites in stage II colorectal cancer patients: The DACHS study

2019 ◽  
Vol 145 (1) ◽  
pp. 221-231 ◽  
Author(s):  
Inna Zaimenko ◽  
Carsten Jaeger ◽  
Hermann Brenner ◽  
Jenny Chang‐Claude ◽  
Michael Hoffmeister ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Stage Ii ◽  
Plasma Metabolites ◽  
Non Invasive ◽  
Stage Ii Colorectal Cancer ◽  
Colorectal Cancer Patients

scholarly journals POTENTIAL PREVENTIVE EFFECT OF LACTOBACILLUS ACIDOPHILUS AND LACTOBACILLUS PLANTARUM IN PATIENTS WITH POLYPS OR COLORECTAL CÂNCER

2018 ◽  
Vol 55 (4) ◽  
pp. 407-411 ◽  
Author(s):  
Nazi ZINATIZADEH ◽  
Farzad KHALILI ◽  
Parviz FALLAH ◽  
Malihe FARID ◽  
Maryam GERAVAND ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Lactobacillus Plantarum ◽  
Lactobacillus Acidophilus ◽  
Rrna Gene ◽  
Preventive Effect ◽  
Healthy Group ◽  
Significant Difference ◽  
Average Copy ◽  
And Gender ◽  
Colorectal Cancer Patients

ABSTRACT BACKGROUND: Colorectal cancer is one of the major causes of death worldwide. Many studies have been done on the biology of its formation as well as its treatment in recent years. One of the factors involved in the formation or treatment of this malignancy can be attributed to the microbial flora in the intestine. OBJECTIVE: This study investigate the potential preventive effect of Lactobacillus acidophilus and Lactobacillus plantarum in patients with polyps or colorectal cancer (CRC). METHODS: A total of 77 samples were selected in the form of three groups including individuals suffering from CRC, polyps and healthy subjects. Genomic DNA of fecal specimens and standard strains were extracted and amplified employing primers targeting of the 16S rRNA gene for initial detection. Absolute Real Time PCR quantification was used to determine the copy of the bacterial expression per gram of feces. RESULTS: No significant difference were observed between age and gender in the mentioned groups (P=0.06). The average copy number of Lactobacillus acidophilus shows Significant difference between the healthy group and those with polyps (P<0.0001), the healthy group and those with colorectal cancer (P<0.0001), as well as those with polyps and the colorectal cancer patients (P<0.0001). CONCLUSION: These results may indicate that taking Lactobacillus acidophilus in people with a family history of CRC and people with polyps may be a way of preventing, treating or reducing the severity of CRC.

scholarly journals HUMAN DNA QUANTIFICATION IN THE STOOLS OF PATIENTS WITH COLORECTAL CANCER

2015 ◽  
Vol 52 (4) ◽  
pp. 293-298 ◽  
Author(s):  
Yolanda TEIXEIRA ◽  
Jacqueline Miranda LIMA ◽  
Maria Luiza Almeida Prado Oliveira SOUZA ◽  
Pedro AGUIAR Jr ◽  
Tiago Donizetti SILVA ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Cells ◽  
Cancer Patients ◽  
Roc Curve ◽  
Dna Quantification ◽  
Non Invasive ◽  
Human Dna ◽  
The World ◽  
Invasive Method ◽  
Colorectal Cancer Patients

Background - Colorectal cancer is one of the main cause of cancer in the world. Colonoscopy is the best screen method, however the compliance is less than 50%. Quantification of human DNA (hDNA) in the feces may be a possible screen non-invasive method that is a consequence of the high proliferation and exfoliation of cancer cells. Objective - To quantify the human DNA in the stools of patients with colorectal cancer or polyps. Methods - Fifty patients with CRC, 26 polyps and 53 with normal colonoscopy were included. Total and human DNA were analyzed from the frozen stools. Results - An increased concentration of hDNA in the stools was observed in colorectal cancer patients compared to controls and polyps. Tumors localized in the left side of the colon had higher concentrations of hDNA. There were no difference between polyps and controls. A cut off of 0.87 ng/mL of human DNA was determined for colorectal cancer patients by the ROC curve, with a sensitivity of 66% and a specificity of 86.8%. For polyps the cut off was 0.41, the sensitivity was 41% and the specificity 77.4%. Conclusion - A higher concentration of hDNA had been found in colorectal cancer patients The quantification of hDNA from the stools can be a trial method for the diagnosis of colorectal cancer.

scholarly journals Urinary Measurement of Epigenetic DNA Modifications: A Non-Invasive Assessment of the Whole-Body Epigenetic Status in Healthy Subjects and Colorectal Cancer Patients

ChemistryOpen ◽  
2016 ◽  
Vol 5 (6) ◽  
pp. 550-553 ◽  
Author(s):  
Rafal Rozalski ◽  
Daniel Gackowski ◽  
Agnieszka Siomek-Gorecka ◽  
Zbigniew Banaszkiewicz ◽  
Ryszard Olinski
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Healthy Subjects ◽  
Whole Body ◽  
Non Invasive ◽  
Dna Modifications ◽  
Colorectal Cancer Patients

Plasma protein-bound sialic acid in patients with colorectal polyps of known histology

1991 ◽  
Vol 37 (2) ◽  
pp. 200-204 ◽  
Author(s):  
Shahram Shahangian ◽  
Herbert A Fritsche ◽  
John I Hughes ◽  
Richard S Foemmel ◽  
Nonda Katopodis
Keyword(s):  
Colorectal Cancer ◽  
Sialic Acid ◽  
Cancer Patients ◽  
Healthy Subjects ◽  
Mean Value ◽  
Colorectal Polyps ◽  
Hyperplastic Polyps ◽  
The Mean ◽  
Colorectal Cancer Patients ◽  
Colorectal Adenocarcinomas

Abstract Protein-bound sialic acid (PBSA) was measured in serial plasma specimens from 62 healthy subjects, 48 patients with colorectal polyps, and 30 patients with colorectal adenocarcinomas. The mean plasma PBSA concentration in healthy smokers was significantly greater than that in healthy nonsmokers and healthy ex-smokers (P less than 0.0001). Villoglandular polyps were associated with higher plasma PBSA values than were the most benign hyperplastic polyps (P less than 0.025). Patients with the most neoplastic villoglandular and villous polyps had significantly greater (P less than 0.010-0.050) plasma PBSA values than healthy subjects. Polypectomy decreased the mean PBSA value significantly to the mean value for healthy subjects only for patients with villoglandular (P less than 0.010) or villous (P less than 0.050) polyps. Colorectal cancer patients had mean plasma PBSA concentrations significantly greater than those for the healthy subjects (P much less than 0.001) and the polyp patients (P much less than 0.001). Surgery significantly reduced (P less than 0.025) the mean PBSA value for the cancer patients to the mean PBSA value observed for the healthy subjects.

scholarly journals piRNA-823 Is a Unique Potential Diagnostic Non-Invasive Biomarker in Colorectal Cancer Patients

Genes ◽  
2021 ◽  
Vol 12 (4) ◽  
pp. 598
Author(s):  
Norhan A. Sabbah ◽  
Wael M. Abdalla ◽  
Walid A. Mawla ◽  
Nagla AbdAlMonem ◽  
Amal F. Gharib ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Characteristic Curve ◽  
Area Under The Curve ◽  
Serum Levels ◽  
P Element ◽  
Serum Samples ◽  
Expression Levels ◽  
Non Invasive ◽  
Colorectal Cancer Patients

Early detection of colorectal cancer (CRC) is the most important factor in deciding its prognosis, so the need to develop an accurate screening test is a must. P-element induced wimpy testis (PIWI) RNA-823 (piR-823) is one of the first piRNAs recognized to be linked to malignancy. We aimed to investigate the expression levels of piR-823 in both serum and tissues of colorectal cancer patients and the ability to use its serum level as a non-invasive diagnostic biomarker to detect colorectal cancer. We determined piR-823 expression levels in 84 serum samples of CRC patients, 75 serum samples of healthy controls, and biological specimens obtained from the 84 patients with colorectal cancer from both the tumor tissues and the normal neighboring tissues using quantitative real-time reverse transcriptase-PCR. We showed that piR-823 had significantly higher serum and tissue expression levels in CRC patients compared to the controls. We observed a significant positive correlation between piR-823 serum levels and the staging of CRC, with significantly higher levels exhibiting advanced stages of CRC (III and IV). This translates into poorer differentiation and lymph node metastasis. The receiver operating characteristic curve (ROC curve) test showed 83.3% sensitivity and 89.3% specificity at a cut-off value of >5.98-fold change, with an area under the curve of 0.933 (p < 0.0001) concerning the ability of piR-823 in diagnosing patients with colorectal carcinoma. piR-823 expression is upregulated in colorectal cancer patients’ serum and tissues, and it can be used as a diagnostic noninvasive biomarker for CRC.

scholarly journals Circadian and chemotherapy-related changes in urinary modified nucleosides excretion in patients with metastatic colorectal cancer

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
S. Dulong ◽  
Q. Huang ◽  
P. F. Innominato ◽  
A. Karaboue ◽  
M. Bouchahda ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Urinary Excretion ◽  
Metastatic Colorectal Cancer ◽  
Cellular Proliferation ◽  
Activity Rhythm ◽  
Modified Nucleosides ◽  
Non Invasive ◽  
Circadian Control ◽  
Colorectal Cancer Patients ◽  
Rest Activity

AbstractUrinary levels of modified nucleosides reflect nucleic acids turnover and can serve as non-invasive biomarkers for monitoring tumour circadian dynamics, and treatment responses in patients with metastatic colorectal cancer. In 39 patients, median overnight urinary excretion of LC-HRMS determinations of pseudouridine, was ~ tenfold as large as those of 1-methylguanosine, 1-methyladenosine, or 4-acetylcytidine, and ~ 100-fold as large as those of adenosine and cytidine. An increase in any nucleoside excretion after chemotherapy anticipated plasma carcinoembryonic antigen progression 1–2 months later and was associated with poor survival. Ten fractionated urines were collected over 2-days in 29 patients. The median value of the rhythm-adjusted mean of urinary nucleoside excretion varied from 64.3 for pseudouridine down to 0.61 for cytidine. The rhythm amplitudes relative to the 24-h mean of 6 nucleoside excretions were associated with rest duration, supporting a tight link between nucleosides turnover and the rest-activity rhythm. Moreover, the amplitude of the 1-methylguanosine rhythm was correlated with the rest-activity dichotomy index, a significant predictor of survival outcome in prior studies. In conclusion, urinary excretion dynamics of modified nucleosides appeared useful for the characterization of the circadian control of cellular proliferation and for tracking early responses to treatments in colorectal cancer patients.

scholarly journals Highly-specific early detection of colorectal cancer by novel non-invasive serum methylation biomarkers

2021 ◽  
Author(s):  
Maria Gallardo-Gomez ◽  
Mar Rodriguez-Girondo ◽  
Nuria Planell ◽  
Sebastian Moran ◽  
Luis Bujanda ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Early Detection ◽  
Blood Test ◽  
Serum Samples ◽  
Screening Programs ◽  
Non Invasive ◽  
Incidence And Mortality ◽  
Sample Pooling ◽  
Immunochemical Test ◽  
Advanced Adenomas

Early detection has proven to be the most effective strategy to reduce the incidence and mortality of colorectal cancer (CRC). Nevertheless, most current screening programs suffer from low participation rates. A blood test may improve both the adherence to screening and the selection to colonoscopy. In this study, we conducted a serum-based discovery and validation of cfDNA methylation biomarkers for CRC screening in a multicentre cohort of 453 serum samples including healthy controls, benign pathologies, advanced adenomas (AA), and CRC. First, we performed an epigenome-wide methylation analysis with the MethylationEPIC array using a sample pooling approach, followed by a robust prioritization of candidate biomarkers for the detection of advanced neoplasia (AN: AA and CRC). Then, candidate biomarkers were validated by pyrosequencing in independent individual cfDNA samples. We report GALNT9, UPF3A, WARS, and LDB2 as new non-invasive biomarkers for the early detection of AN. The combination of GALNT9/UPF3A by logistic regression discriminated AN with 78.8% sensitivity and 100% specificity, outperforming the commonly used fecal immunochemical test and the methylated SEPT9 blood test. Overall, our results suggest that the combination methylated GALNT9/UPF3A has the potential to serve as a highly specific and sensitive blood-based test for screening and early detection of CRC.

scholarly journals Inter- and intra-patient circadian variabilities in eight urinary modified nucleosides excretion in patients with metastatic colorectal cancer

2019 ◽  
Author(s):  
Sandrine Dulong ◽  
Huang Qi ◽  
Innominato Pasquale Fabio ◽  
Karaboue Abdoulaye ◽  
Bouchahda Mohamed ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Urinary Excretion ◽  
Cellular Proliferation ◽  
Modified Nucleosides ◽  
Activity Data ◽  
Medical Treatments ◽  
Non Invasive ◽  
R1 Resection ◽  
Circadian Timing System ◽  
Colorectal Cancer Patients

Abstract Background : Modified nucleosides reflect nucleic acids turnover, and are eliminated into the urine. They can serve as non-invasive biomarkers for monitoring tumour dynamics, and treatment responses. Methods : 8 modified nucleosides were determined by LC-HRMS in urine voids collected in three linical trials recorded on NCT01693848, NCT01693861 and NCT01693835 by a total of 39 patients. The patients’ circadian timing system was studied by wrist actimetry. Rhythms parameters were estimated using Hidden Markov model (HMM) for telemetric activity data and cosinor analysis for urinary nucleosides excretion. Results : Pseudouridine, was ~ 10-fold larger than those of 1-methylguanosine, 1-methyladenosine, or 4-acetylcytidine, and ~100 fold larger than those of adenosine and cytidine. In St 1, a significant increase in the overnight urinary excretion of 1-methylguanosine was associated with prolonged 4-year survival in patients with R1 resection for liver metastases. In St 2, a significant increase in one nucleoside excretion after chemotherapy was associated with that in plasma carcinoembryonic antigen 1-2 months later, and poor survival. In St3, ten fractionated urines were collected over 2-days. Circadian and/or 12-h rhythms were found in up to 48.3% of the patients for pseudouridine. Rhythm amplitudes were significantly associated with rest-activity circadian parameters. Conclusion : Urinary excretion dynamics of modified nucleosides appeared useful for tracking early responses to surgical or medical treatments, and for characterizing circadian control of cellular proliferation in colorectal cancer patients.

scholarly journals Circulating microRNAs as Promising Biomarkers in Colorectal Cancer

Cancers ◽  
2019 ◽  
Vol 11 (7) ◽  
pp. 898 ◽  
Author(s):  
Óscar Rapado-González ◽  
Ana Álvarez-Castro ◽  
Rafael López-López ◽  
José Iglesias-Canle ◽  
María Mercedes Suárez-Cunqueiro ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Circulating Mirnas ◽  
Therapeutic Approaches ◽  
Clinical Context ◽  
Circulating Micrornas ◽  
Non Invasive ◽  
Promising Tool ◽  
Clinical Potential ◽  
Late Stages ◽  
Selection Of

Colorectal cancer (CRC) is one of the most common cancers and a leading cause of cancer-related deaths worldwide. Despite numerous advances in therapeutic approaches, this cancer has a poor prognosis when it is diagnosed at late stages. Therefore, the scientific effort is nowadays directed towards the development of new non-invasive and dynamic biomarkers to improve the survival expectancy of CRC patients. In this sense, deregulated expression of many miRNAs has been shown to play an important role for CRC carcinogenesis and dissemination. Noticeably, an increasing number of studies highlight that circulating miRNAs, including those traveling inside exosomes or those released by tumor cells into circulation, constitute a promising tool for early detection, prognosis and therapy selection of CRC. Therefore, in this review we focus on the clinical potential of blood circulating miRNAs as emerging biomarkers with high value to improve the clinical management of CRC patients, providing a deep and complete perspective of the realities and challenges to translate these biomarkers to the clinical context.

Sign in / Sign up

Export Citation Format

Share Document